Company Encyclopedia
View More
name
Merck
MKKGY.US
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies.
4.582 T
MKKGY.USMarket value -Rank by Market Cap -/-

Financial Score

18/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking42/185
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.33%B
    • Profit Margin13.90%B
    • Gross Margin60.42%A
  • Growth ScoreC
    • Revenue YoY3.73%C
    • Net Profit YoY12.09%C
    • Total Assets YoY6.68%B
    • Net Assets YoY7.28%B
  • Cash ScoreC
    • Cash Flow Margin719.59%B
    • OCF YoY3.73%C
  • Operating ScoreC
    • Turnover0.42C
  • Debt ScoreC
    • Gearing Ratio43.06%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    FDA grants fast track designation for Merck KGAA's cladribine capsules for the treatment of gMG

    FDA grants fast track designation for Merck KGAA's cladribine capsules for the treatment of gMG

    marketscreener·
    US
    MKKGY
    -2.45%
    marketscreener·
    US
    MKKGY
    -2.45%

    Merck KGaA and Valo will use artificial intelligence (AI) technology to develop drugs for Parkinson's disease

    Wallstreetcn·
    US
    MKKGY
    -2.45%
    Wallstreetcn·
    US
    MKKGY
    -2.45%

    Valo Health announces collaboration with Merck KGAA, Darmstadt, Germany

    Valo Health announces collaboration with Merck KGAA, Darmstadt, Germany

    marketscreener·
    US
    MKKGY
    -2.45%
    marketscreener·
    US
    MKKGY
    -2.45%

    Merck Signs Renewable Energy Contract For South Korea Sites

    MERCK KGAA :MERCK KGAA, DARMSTADT, GERMANY SIGNS LONG-TERM RENEWABLE ENERGY CONTRACT FOR SOUTH KOREA SITES20-YEAR POWER PURCHASE AGREEMENT WITH SK INNOVATION E&S TO ADD 16 MW OF RENEWABLE ELECTRICITY CAPACITY STARTING IN DECEMBER 2027

    Reuters·
    US
    MKKGY
    -2.45%
    Reuters·
    US
    MKKGY
    -2.45%

    Merck Publishes Long-Term Efficacy And Safety Data From Phase 3 Defi Trial Of Ogsiveo®

    MERCK KGAA :MERCK KGAA - ANNOUNCES PUBLICATION OF LONG-TERM EFFICACY AND SAFETY DATA FROM THE PHASE 3 DEFI TRIAL OF OGSIVEO® (NIROGACESTAT) MERCK KGAA - LONG-TERM CONTINUOUS OGSIVEO TREATMENT FOR UP TO 4 YEARS WAS ASSOCIATED WITH FURTHER TUMOR SIZE REDUCTIONS, INCREASE IN OBJECTIVE RESPONSE RATEMERCK KGAA - SUSTAINED IMPROVEMENT IN DESMOID TUMOR SYMPTOMS AND CONSISTENT SAFETY PROFILE

    Reuters·
    US
    MKKGY
    -2.45%
    Reuters·
    US
    MKKGY
    -2.45%
    © 2025 Longbridge｜Disclaimer